See more : Public Service Company of New Mexico PFD 4.58% (PNMXO) Income Statement Analysis – Financial Results
Complete financial analysis of Zealand Pharma A/S (ZLDPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zealand Pharma A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Angi Inc. (ANGI) Income Statement Analysis – Financial Results
- Biomagnetics Diagnostics Corp. (BMGP) Income Statement Analysis – Financial Results
- C WorldWide Globale Aktier – AK (CWIGAAKKKLA.CO) Income Statement Analysis – Financial Results
- Sun Art Retail Group Limited (SURRY) Income Statement Analysis – Financial Results
- Track Group, Inc. (TRCK) Income Statement Analysis – Financial Results
Zealand Pharma A/S (ZLDPF)
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 342.79M | 103.99M | 292.57M | 353.31M | 41.33M | 37.98M | 139.78M | 234.78M | 187.68M | 153.77M | 6.57M | 223.57M | 142.28M | 87.36M | 25.32M | 56.26M | 59.92M |
| Cost of Revenue | 19.17M | 30.71M | 118.81M | 90.57M | 415.00K | 180.24M | 14.63M | 31.46M | 22.27M | 13.78M | 872.00K | 15.93M | 112.00K | 11.20M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 323.61M | 73.28M | 173.75M | 262.75M | 40.92M | -142.26M | 125.15M | 203.32M | 165.41M | 140.00M | 5.70M | 207.63M | 142.17M | 76.15M | 25.32M | 56.26M | 59.92M |
| Gross Profit Ratio | 94.41% | 70.47% | 59.39% | 74.37% | 99.00% | -374.60% | 89.53% | 86.60% | 88.14% | 91.04% | 86.74% | 92.87% | 99.92% | 87.18% | 100.00% | 100.00% | 100.00% |
| Research & Development | 684.90M | 614.04M | 588.45M | 604.08M | 561.42M | 438.22M | 324.67M | 268.16M | 214.96M | 180.04M | 164.47M | 182.76M | 126.94M | 151.28M | 93.09M | 85.76M | 105.14M |
| General & Administrative | 73.80M | 274.24M | 260.99M | 202.77M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Selling & Marketing | 16.05M | 32.30M | 375.27M | 285.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.85M | 306.54M | 636.26M | 488.03M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Other Expenses | 121.10M | 0.00 | -759.00K | -602.00K | -444.00K | 1.10B | 0.00 | 777.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 895.85M | 920.59M | 1.22B | 1.09B | 628.86M | 515.59M | 371.53M | 318.97M | 246.74M | 213.53M | 191.32M | 175.24M | 133.41M | 196.05M | 105.24M | 100.95M | 122.45M |
| Cost & Expenses | 915.03M | 920.59M | 1.34B | 1.18B | 629.28M | 695.82M | 386.16M | 350.42M | 269.00M | 227.31M | 192.19M | 191.17M | 133.52M | 196.05M | 105.24M | 100.95M | 122.45M |
| Interest Income | 45.32M | 6.54M | 44.00K | 895.00K | 5.41M | 4.26M | 2.05M | 592.00K | 139.00K | 719.00K | 3.04M | 5.63M | 6.56M | 4.13M | 4.32M | 11.21M | 0.00 |
| Interest Expense | 24.89M | 56.46M | 4.09M | 2.90M | 3.21M | 15.08M | 18.91M | 32.16M | 32.71M | 2.02M | 81.00K | 186.00K | 1.95M | 63.00K | 104.00K | 257.00K | 0.00 |
| Depreciation & Amortization | 25.09M | 30.71M | 25.12M | 42.69M | 13.54M | 4.51M | 4.76M | 5.41M | 6.22M | 5.93M | 5.91M | 5.32M | 4.13M | 4.13M | 3.69M | 3.28M | 0.00 |
| EBITDA | -658.89M | -665.26M | -711.85M | -627.94M | -562.64M | -442.00M | -246.28M | -118.27M | -81.25M | -64.54M | -177.68M | 41.92M | 14.68M | -104.57M | -76.25M | -44.69M | -62.53M |
| EBITDA Ratio | -192.22% | -639.76% | -332.94% | -246.80% | -1,361.23% | -1,761.72% | -176.19% | -50.37% | -45.11% | -43.50% | -2,687.30% | 19.39% | 13.67% | -119.71% | -284.06% | -79.43% | -104.35% |
| Operating Income | -572.24M | -816.60M | -1.05B | -828.76M | -587.94M | 652.39M | -246.38M | -115.65M | -81.33M | -73.54M | -185.62M | 32.40M | 8.76M | -108.70M | -79.93M | -44.69M | -62.53M |
| Operating Income Ratio | -166.94% | -785.30% | -358.96% | -234.57% | -1,422.45% | 1,717.86% | -176.27% | -49.26% | -43.33% | -47.82% | -2,823.52% | 14.49% | 6.16% | -124.43% | -315.67% | -79.43% | -104.35% |
| Total Other Income/Expenses | -136.63M | -134.89M | 25.43M | -47.29M | 11.27M | -27.33M | -31.39M | -43.76M | -38.51M | 1.05M | 1.94M | 3.98M | 4.61M | 4.06M | 4.86M | 10.96M | 7.53M |
| Income Before Tax | -708.87M | -972.04M | -1.03B | -839.65M | -576.68M | 625.06M | -277.77M | -159.41M | -119.83M | -72.49M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Income Before Tax Ratio | -206.79% | -934.78% | -351.01% | -237.65% | -1,395.20% | 1,645.88% | -198.73% | -67.90% | -63.85% | -47.14% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| Income Tax Expense | -5.13M | -6.43M | -8.79M | 7.08M | -5.14M | 43.77M | -5.50M | -5.50M | -5.88M | -7.50M | 81.00K | 186.00K | 6.56M | 0.00 | 4.32M | -3.28M | 0.00 |
| Net Income | -703.74M | -965.61M | -1.02B | -846.73M | -571.54M | 581.28M | -272.27M | -153.91M | -113.96M | -64.99M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Net Income Ratio | -205.30% | -928.60% | -348.01% | -239.65% | -1,382.77% | 1,530.61% | -194.79% | -65.56% | -60.72% | -42.26% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| EPS | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.61 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| EPS Diluted | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.60 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| Weighted Avg Shares Out | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.69M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.63M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
| Weighted Avg Shares Out (Dil) | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.70M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.73M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
Zealand Pharma A/S (ZLDPF) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to earnings of $0.18 per share a year ago.
Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4
Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.
Zealand Pharma seeks partner for its 'next generation' weight loss drug
CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.
Zealand Pharma targeting 'next generation' of obesity drugs, CEO says
Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.
Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly. CEO Adam Steensberg heralded early-stage trial results of its GLP-1 treatment in an interview...
Recent Price Trend in Zealand Pharma AS (ZLDPF) is Your Friend, Here's Why
Zealand Pharma AS (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zealand Pharma AS (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
Zealand Pharma AS (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price...
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the...
Here's Why Momentum in Zealand Pharma AS (ZLDPF) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Source: https://incomestatements.info
Category: Stock Reports
What are the future financial projections for Zealand Pharma?
Zealand Pharma AS (OCSE:ZEAL) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $54.77 million, and the earnings are expected to come in at -$4.06 per share.
What is Zealand Pharma’s revenue for 2024?
Revenue estimates for Zealand Pharma AS (OCSE:ZEAL) have declined from $190.56 million to $163.57 million for the full year 2024 and from $0.83 billion to $0.73 billion for 2025 over the past 90 days.